Corrigan-Curay emphasized that Journavx could “mitigate certain risks associated with using an opioid for pain.” The FDA’s official account on X also tweeted the news — the agency’s ...

Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

Dr. Adriane Fugh-Berman, a professor of pharmacology and physiology at Georgetown University Medical Center, welcomed the FDA approval. But she contended it was premature to declare that Journavx ...

The medication will be sold under the brand name Journavx for $15.50 per pill, according to Vertex Pharmaceuticals, the company that developed the new drug. The FDA's sign-off on the medication ...

The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain ... drug pipeline that involves winning FDA approval for multiple drugs across several ...

The FDA's approval process for Journavx included an evaluation of its safety and efficacy. Clinical trials demonstrated that the drug is effective in managing acute pain without the adverse ...

The approval was announced in an FDA press release, and it will be sold under the brand name Journavx by Vertex Pharmaceuticals. This painkiller's approval reflects the FDA’s commitment to ...

The U.S. Food and Drug Administration (FDA) has approved a new drug for the treatment of moderate-to-severe pain that is a non-opioid and carries less risks of addiction than opioids. Journavx ...

On Thursday, the Food and Drug Administration (FDA) granted approval to Vertex Pharmaceuticals' non-opioid painkiller pill, a new alternative for pain relief that does not carry the risk of addiction.